A Randomized, Open Label Multicenter Trial to Investigate the Efficacy of a Treat-to-target (T2T) Treatment Strategy With Secukinumab (AIN457) as a First-line Biologic Compared to a Standard-of-care (SOC) Treatment Over 36 Weeks in Patients With Active Axial Spondyloarthritis (axSpA)

This is a randomized, parallel-group, open-label, multicenter study of patients with active axSpA. The aim is to demonstrate that the efficacy of a Treat-to-Target (T2T) approach (with secukinumab as first-line biologic) is superior to a Standard-Of-Care (SOC) approach in terms of achieving strong clinical efficacy in patients with active axial Spondyloarthritis (axSpA) who are naïve to biological therapy and who have had an inadequate response to non-steroidal anti-inflammatory drugs. The study will include an 8-week Screening period, a 36-week treatment period according to previous randomization, and a safety follow-up period of 20 weeks. The primary endpoint is the percentage of patients achieving an Assessment in SpondyloArthritis international Society response 40 (ASAS40) at Week 24.

Start Date04 Jun 2019

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT02744755 / CompletedPhase 3

A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis

Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis

Start Date31 Mar 2016

Sponsor / Collaborator

Sandoz AG

[+1]

NCT02706704 / RecruitingPhase 2IIT

Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis

The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.

Start Date01 Feb 2016

Sponsor / Collaborator

American University of Beirut Medical Center

100 Clinical Results associated with Adalimumab biosimilar (Sandoz)

100 Translational Medicine associated with Adalimumab biosimilar (Sandoz)

100 Patents (Medical) associated with Adalimumab biosimilar (Sandoz)

Literatures (Medical) associated with Adalimumab biosimilar (Sandoz)

01 Sep 2024·Current rheumatology reviews

Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report

Article

Author: Voulgari, Paraskevi V ; Drosos, Alexandros A ; Venetsanopoulou, Aliki I ; Pelechas, Eleftherios ; Mavridou, Konstantina

Background::

Tumor necrosis factor alpha (TNFα) is a pivotal cytokine involved in the pathogenesis of certain inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies, and inflammatory bowel diseases. In the last two decades, TNFα inhibitors (TNFi) have revolutionized the treatment and outcome of the above disorders. However, the use of TNFi has been associated with the development of many autoimmune phenomena and paradoxical skin manifestations that may present as the same type of clinical indications for which the TNFi effectively used. Thus, they may display as arthritis, uveitis, colitis, psoriasis, and several other cutaneous clinical manifestations, among them the development of morphea, a localized scleroderma skin lesion.

Case Presentation::

We describe a 58-year-old woman with seronegative RA, refractory to methotrexate, who was treated with ABP-501 (Hefiya), an adalimumab (ADA) biosimilar and developed an oval-shaped, deep skin lesion of approximately 3.5cm in size, affecting the left part of her back compatible with morphea 3 months after the initiation of therapy. ADA biosimilar was discontinued and two months later, she had substantial skin improvement.

Conclusion::

This is the first report of morphea manifestation during TNFi biosimilar since the patient had no other trigger factors for morphea development like trauma and infections. Physicians dealing with patients treated with TNFi biosimilars should be aware of paradoxical skin reactions, among them morphea; thus, close monitoring, a minute and careful clinical examination, and a follow- up check are required.

01 Sep 2024·JID innovations : skin science from molecules to population health

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

Article

Author: Ma, Keying ; Chen, Yanqing ; Papp, Kim A ; Muñoz-Elías, Ernesto J ; Scott, Brittney ; Blauvelt, Andrew ; Campbell, Kim ; DePrimo, Samuel ; Langley, Richard G ; Branigan, Patrick J ; Liu, Xuejun

Background:

Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23-driven IL-17-producing T cell and other IL-23 receptor-positive IL-17-producing cell responses. Selective blockade of IL-23p19 with guselkumab was superior to blockade of TNF-α with adalimumab (ADA) in treating moderate-to-severe psoriasis. Objective: Pharmacodynamic responses of guselkumab versus ADA were compared in patients with psoriasis in VOYAGE 1.

Design:

Inflammatory cytokine serum levels were assessed (n = 118), and lesional and nonlesional skin biopsies were collected (n = 38) in patient subsets at baseline and 4, 24, and 48 weeks after treatment to evaluate pharmacodynamic responses of guselkumab versus those of ADA.

Results:

Guselkumab provided rapid reductions in serum IL-17A, IL-17F, and IL-22 levels by week 4 versus at baseline, which were maintained through weeks 24 and 48 (P < .001). The magnitude of reduction of IL-17A and IL-22 at week 48 and IL-17F at weeks 4, 24, and 48 were greater with guselkumab than with ADA (all P < .05). In the skin, guselkumab reduced the expression of IL-23/IL-17 pathway-associated and psoriasis-associated genes.

Conclusion:

These data provide extensive characterization of pharmacodynamic anti-inflammatory responses to IL-23p19 and TNF-α inhibition in human blood and tissue over time with FDA-approved doses of guselkumab and ADA. Trial registration:ClinicalTrials.govClinicalTrials.gov (NCT02207231).

01 Aug 2024·Journal of Pediatric Health Care

Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience

Article

Author: Di Sessa, Anna ; Gicchino, Maria Francesca ; Olivieri, Alma Nunzia ; Miraglia del Giudice, Emanuele ; Capasso, Giusy ; Amodio, Alessia

INTRODUCTION:

We aimed to evaluate the efficacy, safety, and immunogenicity profile of Etanercept (ETA) and Adalimumab (ADA) biosimilars (BIOs) compared to their originators in children with juvenile idiopathic arthritis (JIA).

METHOD:

Eighty-one JIA children treated with ETA or ADA originators or BIOs were examined at baseline (T0) and after 3- (T1), 6- (T2), 12- (T3), and 24-(T4) months after starting treatment.

RESULTS:

Lower Juvenile Arthritis Disease Activity Score 10 (JADAS-10) scores were reported at T1, T2, T3, and T4 in JIA children treated with BIOs than originators (all p < 0.05). At T1 and T3, anti-drugs antibodies levels were lower in children receiving BIOs than originators (p = 0.04 and p = 0.0007, respectively), even after adjustments (both p < 0.05). Relapses were lower for BIOs compared to originators (p < 0.001). Safety profile was comparable between the groups (p > 0.05).

DISCUSSION:

A better overall profile of BIOs than originators was demonstrated in JIA children, but larger confirmatory studies are needed.

News (Medical) associated with Adalimumab biosimilar (Sandoz)

30 Oct 2024

·www.globenewswire.com

Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (from mid- to high-single digit) and core EBITDA margin² guidance of around 20% confirmed Basel, October 30, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the third quarter and nine months ended September 30, 2024. For the third quarter, net sales were USD 2.6 billion, an increase of 12% in constant currencies compared to the same quarter of the prior year. For the first nine months of 2024, net sales were USD 7.6 billion, an increase of 9% in constant currencies compared to the prior year. Richard Saynor, Chief Executive Officer of Sandoz, said: “We remain focused on execution, meeting key milestones in our biosimilars business and progressing on our journey as a standalone company. In recent months, we received approval for Pyzchiva® and Enzeevu™ in the US, launched Pyzchiva® in Europe and see continued strong uptake of Hyrimoz® in the US. “Net sales growth was achieved across generics and biosimilars, with generics accelerating in the third quarter and strong double-digit biosimilars growth in both the third quarter and first nine months. Additionally, all three regions contributed to this strong performance. We expect momentum in our business to continue, driving margin expansion through favorable product mix and leveraging our cost base. We have further advanced on our path to simplifying our business, including progression on the transformation program we launched earlier this year.” THIRD-QUARTER AND NINE-MONTH SALES Net sales for the third quarter were USD 2.6 billion, up 12% in constant currencies, compared to the third quarter of 2023. Volume contributed 13 percentage points of growth. This was partially offset by price erosion of 1 percentage point. Biosimilars were the key driver of growth in the quarter, while generics experienced solid demand. Growth accelerated in both businesses. Net sales for the first nine months of 2024 were USD 7.6 billion, up 9% in constant currencies compared to prior year. Volume contributed 11 percentage points of growth. This was partially offset by price erosion of 2 percentage points. The growth was primarily driven by biosimilars, with strong demand for both the base business and new in-market organic and acquired products in the US. Net sales by business Q3 2024Q3 2023 Change % 9M 20249M 2023 Change %USD millions unless indicated otherwise USDcc* USDcc*Generics 1 8541 794 34 5 5585 512 12Biosimilars 741 543 3637 2 0841 592 3132Net sales to third parties 2 5952 337 1112 7 6427 104 89 *constant currencies Generics overviewNet sales for the third quarter were USD 1.9 billion, up 4% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 5.6 billion, up 2% in constant currencies versus prior year. Growth in the Europe region accelerated in the third quarter, mainly driven by recent launches. The momentum continued in the International region, aided by demand for the antifungal agent Mycamine® and favorable pricing dynamics, partly offset by the divestment of the Chinese business. North America declined due to timing of new launches in the US. Biosimilars overviewNet sales for the third quarter were USD 741 million, up 37% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 2.1 billion, up 32% in constant currencies versus prior year. The strong double-digit biosimilars growth reflects the uptake of Hyrimoz® (adalimumab) in the US, the acquisition of Cimerli® (ranibizumab), the continued strong demand for our first-ever biosimilar, Omnitrope® (somatropin), and the launches of Tyruko® (natalizumab) and Pyzchiva® (ustekinumab) in Europe. Net sales by region Q3 2024Q3 2023 Change % 9M 20249M 2023 Change %USD millions unless indicated otherwise USDcc USDccEurope 1 3621 204 1312 3 9963 751 76North America 598 510 1718 1 7421 514 1515International 635 623 28 1 9041 839 49Net sales to third parties 2 5952 337 1112 7 6427 104 89 Europe overviewNet sales for the third quarter were USD 1.4 billion, up 12% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 4.0 billion, up 6% in constant currencies versus prior year. Strong growth in biosimilars continues, led by demand for Omnitrope® and the contribution from the recent launches of Tyruko® and Pyzchiva®. Generics momentum accelerated in the third quarter, driven by recent launches and the lapping of the strong prior-year comparison in the first half. North America overviewNet sales for the third quarter were USD 598 million, up 18% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.7 billion, up 15% in constant currencies versus prior year. Growth was driven by the ongoing uptake of Hyrimoz® in the US, the acquisition of Cimerli®, share gain of Omnitrope® in the US and the launch of Wyost®/Jubbonti® in Canada. This was partly offset by a decline in generics sales due to the timing of new launches in the US. International overviewNet sales for the third quarter were USD 635 million, up 8% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.9 billion, up 9% in constant currencies versus prior year. This was primarily a result of strong volume growth across both generics and biosimilars, contribution from the acquisition of Mycamine® in the prior year, favorable price dynamics and recent launches, partly offset by the divestment of the Chinese business in the second quarter. GUIDANCE 2024 On the back of strong momentum in its biosimilars business and solid generics demand, the company is increasing its full-year 2024 net sales guidance to high-single digit growth in constant currencies versus prior year (from mid- to high-single digit) and is confirming its core EBITDA margin guidance of around 20%. THIRD-QUARTER STRATEGIC MILESTONES Sandoz continued to execute on its strategy and passed additional milestones in its biosimilars portfolio. On July 1, the company announced the US FDA approval of biosimilar Pyzchiva® for all indications of the reference medicine. The company intends to launch Pyzchiva® in the US among the first wave of ustekinumab biosimilars in February 2025. On July 25, Sandoz announced the launch of biosimilar Pyzchiva® across Europe to treat chronic inflammatory diseases. Pyzchiva® was the first biosimilar to launch in Europe with all reference medicine strengths, including an initiation dose for Crohn’s disease. On August 12, Sandoz received FDA approval for Enzeevu™ to treat neovascular age-related macular degeneration. This approval further enhances the company’s leading US ophthalmology portfolio and increases access for patients. Launch timing will be dependent on several factors, including the progress and outcome of pending or potential litigation or any potential settlements. KEY LINKS Webcast – Live at 9am CET Analyst call presentationAnalyst consensus DISCLAIMER This media release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.This media release includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion. CONTACTS Global Media Relations contacts Investor Relations contactsGlobal.MediaRelations@sandoz.comInvestor.Relations@sandoz.comSteffen Kurzawa+41 79 800 8501Laurent de Weck+41 79 795 7364Joerg E. Allgaeuer+49 171 838 4838Tamara Hackl+41 79 790 5217 SUPPORTING FINANCIAL INFORMATION Quarterly net sales 2024 Q1 2024Change % Q2 2024Change % Q3 2024Change %USD millions unless indicated otherwise USDcc USDcc USDccGenerics 1 86901 1 835-11 1 85434Biosimilars 6232121 7203537 7413637Net sales to third parties 2 49256 2 55579 2 5951112 Q1 2024Change % Q2 2024Change % Q3 2024Change %USD millions unless indicated otherwise USDcc USDcc USDcc Europe 1 32642 1 30823 1 3621312North America 52466 6202223 5981718International 642412 62759 63528Net sales to third parties 2 49256 2 55579 2 5951112 2023 Q1 2023Change % Q2 2023Change % Q3 2023Change % Q4 2023Change %USD millions unless indicated otherwise USDcc* USDcc* USDcc* USDcc* Generics 1 86826 1 85046 1 79454 1 92066Biosimilars 5161117 5331314 54374 6232926Net sales to third parties 2 38449 2 38358 2 33764 2 5431110 Q1 2023Change % Q2 2023Change % Q3 2023Change % Q4 2023Change %USD millions unless indicated otherwise USDcc* USDcc* USDcc* USDcc* Europe 1 2701016 1 2771412 1 204113 1 272104North America 496-5-3 508-4-2 510-4-3 6152020International 618-14 598-38 623312 656414Net sales to third parties 2 38449 2 38358 2 33764 2 5431110 ¹ Net sales in this document refer systematically to net sales to third parties. In the first nine months of 2023, third-party sales excluded sales to our former parent. Post spin-off, sales to our former parent are reported as third-party sales.² An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024 Attachment 241030_Q3 and 9M Sales 2024_ Media Release.pdf

Drug ApprovalBiosimilarAcquisition

01 Oct 2024

·www.fiercehealthcare.com

Wyden, Brown urge FTC to investigate PBM 'co-manufacturing' arrangements

The Federal Trade Commission kicked off an investigation into the business practices of major pharmacy benefit managers two years ago and released an interim report based on that analysis in July. Two key senators are urging the Federal Trade Commission (FTC) to investigate "co-manufacturing" arrangements that they fear pharmacy benefit managers may be using to stymie competition.Sen. Ron Wyden, D-Oregon, chair of the Senate Finance Committee, as well as committee member Sherrod Brown, D-Ohio, wrote a letter (PDF) to the FTC on Tuesday expressing concern about units formed recently at two major PBMs that seek to manufacture biosimilars that challenge high-cost branded drugs.CVS Health unveiled its Cordavis unit in August 2023, and its first partnership is with drugmaker Sandoz on its Hyrimoz drug, a biosimilar for Humira. Cigna's Evernorth has formed a private label distributor called Quallent Pharmaceuticals, also with the purpose of bringing biosimilars to market.In the letter, the senators say the PBMs contribute consulting services in these partnerships with manufacturers but are not participants in the actual production of the drugs. As such, they said there's a risk that PBMs could take advantage of these co-manufacturing arrangements to reduce competition. For example, they could manufacture a biosimilar product through one of these divisions, set an unfairly high price and then steer patients toward it, the senators argue. When it announced Cordavis, CVS said Hyrimoz would have a price 80% lower than Humira.“The concern with these ‘co-manufacturing’ agreements is that they are a veiled attempt by PBMs to control additional parts of the supply chain which has resulted in additional harm to consumers in the form of fewer drug choices and higher drug costs,” the senators wrote.“We urge the FTC to examine new PBM tactics that appear to create further barriers to competition and harm the ability of consumers to access lower cost prescription drugs," they continued. "It is important we keep a watchful eye on the evolving tactics of PBM megafirms as they proceed with owning more and more of the prescription drug supply chain.” The FTC kicked off an investigation into the business practices of major PBMs two years ago and released an interim report based on that analysis in July. In mid-September, the agency sued the largest firms over the role they play in rising insulin prices.Regulating the PBM market has been a hot topic on the Hill for several years, but a number of bills have stalled in Congress.

10 Sep 2024

·endpts.com

Optum Rx is moving into the biosimilar business with a company it’s calling Nuvaila, and it’s starting out with biosimilars to AbbVie’s blockbuster rheumatoid arthritis drug Humira and J&J’s psoriatic arthritis drug Stelara, according to a formulary update . UnitedHealth Group, which owns Optum Rx, declined to confirm to Endpoints News in June whether the PBM would move into the biosimilar business. Optum Health Solutions, an Optum Rx subsidiary, submitted an application to the US Patent and Trademark Office on June 4 for Nuvaila, which it said is for “procuring biosimilar pharmaceuticals and selling pharmaceuticals to wholesale pharmaceutical distributors.” For Humira, Optum Rx wrote in its update that it will exclude Humira (adalimumab) and prefer FDA-approved biosimilars starting on Jan. 1, 2025 for patients who are new to the therapy. Patients who are currently on Humira, which is also approved for Crohn’s disease and other conditions, will be able to continue on the drug without switching to a biosimilar, but “with improved Humira pricing.” Optum Rx added that the company has decided to wait on preferring only biosimilars until “all drug strengths are interchangeable at the pharmacy without a new prescription, which is expected later in 2025.” For Stelara, Nuvaila will launch the biosimilar under its own private label, marketing it as Wezlana, also on Jan. 1, 2025. Optum touted the benefits of its copycat, including that it’s the first to market, comes with $0 copay support, is latex-free and patients could see plan sponsor savings of up to almost 50% compared to the drug’s list price. Optum is behind its two other biggest PBM competitors, which have already entered the biosimilar market. CVS created a subsidiary to partner with the generics giant Sandoz to sell the Humira biosimilar Hyrimoz, and Cigna’s health services arm Evernorth also plans to offer a cheaper biosimilar of Humira for free.

Drug ApprovalBiosimilar

100 Deals associated with Adalimumab biosimilar (Sandoz)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L04AB04	DB00051

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Uveitis, Intermediate	JP	Fujifilm Kyowa Kirin Biologics Co., Ltd.	16 Feb 2022
Uveitis, Posterior	JP	Fujifilm Kyowa Kirin Biologics Co., Ltd.	16 Feb 2022
Behcet's uveitis	JP	Fujifilm Kyowa Kirin Biologics Co., Ltd.	29 Jun 2020
Panuveitis	JP	Fujifilm Kyowa Kirin Biologics Co., Ltd.	29 Jun 2020
Pustular psoriasis	JP	Fujifilm Kyowa Kirin Biologics Co., Ltd.	29 Jun 2020
Arthritis	AU	Sandoz Pty Ltd.	01 Mar 2019
Polyarticular Juvenile Idiopathic Arthritis	AU	Sandoz Pty Ltd.	01 Mar 2019
Ankylosing Spondylitis	EU	Sandoz GmbH	26 Jul 2018
Ankylosing Spondylitis	IS	Sandoz GmbH	26 Jul 2018
Ankylosing Spondylitis	LI	Sandoz GmbH	26 Jul 2018
Ankylosing Spondylitis	NO	Sandoz GmbH	26 Jul 2018
Arthritis, Psoriatic	EU	Sandoz GmbH	26 Jul 2018
Arthritis, Psoriatic	IS	Sandoz GmbH	26 Jul 2018
Arthritis, Psoriatic	LI	Sandoz GmbH	26 Jul 2018
Arthritis, Psoriatic	NO	Sandoz GmbH	26 Jul 2018
Axial Spondyloarthritis	EU	Sandoz GmbH	26 Jul 2018
Axial Spondyloarthritis	IS	Sandoz GmbH	26 Jul 2018
Axial Spondyloarthritis	LI	Sandoz GmbH	26 Jul 2018
Axial Spondyloarthritis	NO	Sandoz GmbH	26 Jul 2018
Colitis, Ulcerative	EU	Sandoz GmbH	26 Jul 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2021	Not Applicable	Psoriasis \| Arthritis, Psoriatic \| Rheumatoid Arthritis	-	SDZ-ADL (GP2017)	rjbibzmqyy(pqwoiifiwx) = At 1-hour post-dose, 96.6% of HV experienced no pain (VAS score, 0-4 mm) wwcfouheup (teknnmbxmg )	Positive	07 Nov 2021
EULAR2021	Not Applicable	Psoriasis \| Rheumatoid Arthritis	-	SDZ-ADL (GP2017)	tlnoqsvcio(kakoydgupd) = lvxsytlrpq ksdxtrnxkw (jffqdxnnsx )	-	02 Jun 2021
NCT02744755 (ADMYRA, Pubmed \| BioDrugs) Manual	Phase 3	Rheumatoid Arthritis	353	Adalimumab-ADAZ	wornvipkli(wugzasjvsw) = ykeidratza wrvjolqctw (igqutwkovc ) View more	Similar	01 Dec 2020
				adalimumab	wornvipkli(wugzasjvsw) = gckosryufr wrvjolqctw (igqutwkovc ) View more
NCT02016105 (Pubmed \| Br J Dermatol) Manual	Phase 3	Psoriasis	465	GP2017	ykzajiempl(yezsolvkog) = rolkhysbaf oahwygiiqx (rrltmkdvht ) View more	Similar	01 Sep 2018
				ref-ADMB	ykzajiempl(yezsolvkog) = lvhnxqzxcm oahwygiiqx (rrltmkdvht ) View more
NCT02016105 (ADACCESS, CTgov)	Phase 3	Plaque psoriasis	465	GP2017 Adalimumab (GP2017 Adalimumab)	llzllkpyzh(uwlckrkuhg) = lymjxohrup nppozezvbm (uzjstijgnr, rxopgisfvz - bmkibvyeuf) View more	-	07 Apr 2017
				Humira ® Adalimumab (Humira ® Adalimumab)	llzllkpyzh(uwlckrkuhg) = wtvchpybrv nppozezvbm (uzjstijgnr, iuokgmwskd - cozqegjoye) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis